Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

Kirn, 2001, Replication-selective virotherapy for cancer: biological principles, risk management and future directions, Nat Med, 7, 781, 10.1038/89901 Parato, 2005, Recent progress in the battle between oncolytic viruses and tumours, Nat Rev Cancer, 5, 965, 10.1038/nrc1750 Liu, 2007, Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress, Nat Clin Pract Oncol, 4, 101, 10.1038/ncponc0736 Mastrangelo, 1999, Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma, Cancer Gene Ther, 6, 409, 10.1038/sj.cgt.7700066 Yang, 2005, Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction, J Clin Invest, 115, 379, 10.1172/JCI200523220 Thorne, 2007, Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX–963, J Clin Invest, 117, 3350, 10.1172/JCI32727 Kirn, 2007, Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus, PLoS Med, 4, e353, 10.1371/journal.pmed.0040353 Luker, 2005, Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread, Virology, 341, 284, 10.1016/j.virol.2005.06.049 Hengstschlager, 1994, Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells, J Biol Chem, 269, 13836, 10.1016/S0021-9258(17)36723-6 Dranoff, 1993, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity, Proc Natl Acad Sci USA, 90, 3539, 10.1073/pnas.90.8.3539 Breitbach, 2007, Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow, Mol Ther, 15, 1686, 10.1038/sj.mt.6300215 Kim, 2006, Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF, Mol Ther, 14, 361, 10.1016/j.ymthe.2006.05.008 Kulesh, 2004, Smallpox and pan-orthopox virus detection by real-time 3′-minor groove binder TaqMan assays on the roche LightCycler and the Cepheid smart Cycler platforms, J Clin Microbiol, 42, 601, 10.1128/JCM.42.2.601-609.2004 Choi, 2007, Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria, J Clin Oncol, 25, 1753, 10.1200/JCO.2006.07.3049 Cebon, 1992, The dissociation of GM-CSF efficacy from toxicity according to route of administration: a pharmacodynamic study, Br J Haematol, 80, 144, 10.1111/j.1365-2141.1992.tb08891.x Kirn, 2001, Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?, Gene Ther, 8, 89, 10.1038/sj.gt.3301377 Reid, 2002, Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints, Cancer Res, 62, 6070 Reid, 2001, Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial, Gene Ther, 8, 1618, 10.1038/sj.gt.3301512 Kemeny, 2006, Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver, Hum Gene Ther, 17, 1214, 10.1089/hum.2006.17.1214 Liu, 2007, Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions, Cancer Res, 67, 429, 10.1158/0008-5472.CAN-06-2871 Harrison, 2004, Discovery of antivirals against smallpox, Proc Natl Acad Sci USA, 101, 11178, 10.1073/pnas.0403600101 McCart, 2001, Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes, Cancer Res, 61, 8751 Alcami, 1996, A mechanism for the inhibition of fever by a virus, Proc Natl Acad Sci USA, 93, 11029, 10.1073/pnas.93.20.11029 Liu, 2005, Viruses with deletions in antiapoptotic genes as potential oncolytic agents, Oncogene, 24, 6069, 10.1038/sj.onc.1208734 Fulci, 2006, Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses, Proc Natl Acad Sci USA, 103, 12873, 10.1073/pnas.0605496103 Myers, 2007, Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide, Clin Pharmacol Ther, 82, 700, 10.1038/sj.clpt.6100409 Vanderplasschen, 1997, Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation, J Gen Virol, 78, 2041, 10.1099/0022-1317-78-8-2041 Vanderplasschen, 1998, Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope, Proc Natl Acad Sci USA, 95, 7544, 10.1073/pnas.95.13.7544 Smith, 2002, Immune response to poxvirus infections in various animals, Crit Rev Microbiol, 28, 149, 10.1080/1040-840291046722 Wang, 2003, E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models, Nat Biotechnol, 21, 1328, 10.1038/nbt887